Phase I study of dibromodulcitol (NSC-104800).
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000477:Alkylating Agents / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001772:Blood Cell Count; D001966:Bromine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D013402:Sugar Alcohols / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced
D000477:Alkylating Agents; D000970:Antineoplastic Agents; D013402:Sugar Alcohols; D001966:Bromine